In cancer patients, NK cells exhibit lower expression of receptors such as CD16 and NKG2D, alongside reduced survival, proliferation, cytotoxicity, and cytokine production, particularly IFN-γ secretion [55,68,69,70]. This evidence concerns the gene KLRK1 and cancer.